MedTrace Logo

Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists

NCT03412058 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 670

Last updated 2025-02-20

No results posted yet for this study

Summary

This is a prospective cohort study which aims to identify predictive factors of response to PD-1 and PD L1 antagonists authorised for use in France in treatment of melanoma, NSCLC, or HNSCC.

Conditions

Interventions

PROCEDURE

Biopsy

To be performed prior to anti-PD1/PD-L1 treatment initiation

PROCEDURE

Biopsy

To be performed after 42 (±3) days of anti-PD1 or PD-L1 treatment in consenting patients

PROCEDURE

Biopsy

To be performed at disease progression if medically feasible

Sponsors & Collaborators

  • Fondation ARC

    collaborator OTHER

  • UNICANCER

    lead OTHER

Principal Investigators

  • Frédérique Penault-Llorca · Centre Jean Perrin

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-27
Primary Completion
2024-01-02
Completion
2025-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03412058 on ClinicalTrials.gov